Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Glioblastoma

    Boston, MA

    Search
    Glioblastoma
    Boston, MA
    Show Map
    Map View
    Boston, MA

    Popular Searches

    By Condition

    Depression Clinical Trials in Massachusetts

    Anxiety Clinical Trials in Massachusetts

    Schizophrenia Clinical Trials in Massachusetts

    ADHD Clinical Trials in Massachusetts

    Bipolar Disorder Clinical Trials in Massachusetts

    Multiple Sclerosis Clinical Trials in Massachusetts

    Autism Clinical Trials in Massachusetts

    Treatment Resistant Depression Clinical Trials in Massachusetts

    Borderline Personality Disorder Clinical Trials in Massachusetts

    Social Anxiety Disorder Clinical Trials in Massachusetts

    Parkinson's Disease Clinical Trials in Massachusetts

    Alzheimer's Disease Clinical Trials in Massachusetts

    By Location

    Clinical Trials near Boston, MA

    Clinical Trials near Worcester, MA

    Clinical Trials near Springfield, MA

    Clinical Trials near Burlington, MA

    Clinical Trials near Fall River, MA

    Clinical Trials near Cambridge, MA

    Clinical Trials near North Dartmouth, MA

    Clinical Trials near Newton, MA

    Clinical Trials near Waltham, MA

    Clinical Trials near Watertown, MA

    Clinical Trials near Belmont, MA

    Clinical Trials near Brockton, MA

    Other People Viewed

    By Subject

    26 Leiomyosarcoma Trials near Boston, MA

    56 Psoriasis Trials near Boston, MA

    102 Arthritis Trials near Boston, MA

    49 Glioblastoma Trials near Philadelphia, PA

    71 Glioblastoma Trials near Houston, TX

    21 Glioblastoma Trials near Tampa, FL

    91 Parkinson's Disease Trials near Boston, MA

    73 Glioblastoma Trials near Ventura, CA

    Top Clinical Trials near Boston, MA

    Top Osteoporosis Clinical Trials near Boston, MA

    Top Prostate Cancer Clinical Trials near Boston, MA

    Top Recurrent Glioblastoma Clinical Trials

    By Trial

    Niraparib vs Temozolomide for Brain Cancer

    CTO + Temodar® for Glioblastoma

    Pamiparib + Standard Care for Glioblastoma

    Tocilizumab + Atezolizumab + Radiation Therapy for Glioblastoma

    Niacin CRT for Glioblastoma

    GammaTile + Stupp Protocol for Glioblastoma

    Multiple Therapies for Glioblastoma

    Personalized Radiation Therapy for Glioblastoma

    Proton Therapy + Avastin for Recurrent Glioblastoma

    STARLITE for Unresectable Brain Tumors

    Peptide Vaccine for Brain Cancer

    ONC206 + Radiation Therapy for Brain Tumor

    Related Searches

    Top Glioblastoma Clinical Trials near Anaheim, CA

    Top Treatment for Gabapentin Clinical Trials

    Top Treatment for Exparel Clinical Trials

    Telerehabilitation for Stroke

    Bacterial Decolonization for Soft Tissue Sarcoma

    SIESTA Rehab Education for Stroke Recovery

    Sotorasib for Advanced Non-Small Cell Lung Cancer

    Lu AF82422 for Multiple System Atrophy

    Blood Pressure Management for Spinal Cord Injury

    Cleansing Device for Scalp Conditions

    CGuard Prime Stent for Carotid Artery Disease

    Surgery + Medication for Obstructive Sleep Apnea

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      88 Glioblastoma Trials near Boston, MA

      Power is an online platform that helps thousands of Glioblastoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Olutasidenib + Temozolomide for Brain Tumors

      Boston, Massachusetts
      The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:12 - 39

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV, Metastatic HGG, Others
      Must Be Taking:Temozolomide

      60 Participants Needed

      M3554 for Solid Tumors

      Boston, Massachusetts
      The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Other Malignancies, Brain Metastasis, Others

      52 Participants Needed

      IDH305 for Advanced Cancer

      Boston, Massachusetts
      A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiac, Respiratory, Gastrointestinal, Others

      166 Participants Needed

      TNG456 + Abemaciclib for Solid Tumors

      Boston, Massachusetts
      This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Infection, Cardiovascular Disease, Others
      Must Not Be Taking:PRMT5 Inhibitors, MAT2A Inhibitors, CDK4/6 Inhibitors

      191 Participants Needed

      Berubicin for Glioblastoma

      Boston, Massachusetts
      This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Uncontrolled Hypertension, Others
      Must Not Be Taking:Bevacizumab, Lomustine, Others

      210 Participants Needed

      LY3410738 for Solid Tumors

      Boston, Massachusetts
      This trial is testing a new oral drug called LY3410738 in patients with advanced solid tumors that have specific genetic mutations. The drug works by blocking abnormal enzymes to potentially stop or slow cancer growth.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active CNS Metastases, Uncontrolled Cardiac Disease, Others
      Must Not Be Taking:Strong CYP3A4 Inhibitors, P-gp Inhibitors

      200 Participants Needed

      TNG908 for Solid Tumors

      Boston, Massachusetts
      This trial is testing TNG908, an oral drug, in patients with advanced or metastatic solid tumors that have an MTAP deletion. The drug works by blocking a protein that helps these specific cancer cells grow. The study will see if this treatment can help slow down or stop the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Liver Disease, Cardiovascular, Others
      Must Not Be Taking:Antiretrovirals

      192 Participants Needed

      Cobolimab + Dostarlimab for Cancer

      Boston, Massachusetts
      The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:0 - 21

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled CNS Involvement, Cardiovascular Disease, Respiratory Disease, Others
      Must Not Be Taking:Immunosuppressants, Systemic Steroids

      83 Participants Needed

      Repotrectinib for Solid Tumors in Young Patients

      Boston, Massachusetts
      Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:0 - 25

      Key Eligibility Criteria

      Disqualifiers:Neuroblastoma, Active Infections, Cardiac Issues, Others
      Must Not Be Taking:Strong CYP3A4 Inhibitors

      75 Participants Needed

      Selinexor for Pediatric Solid Tumors or Brain Tumors

      Boston, Massachusetts
      This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or central nervous system (CNS) tumors that have come back (recurrent) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:12 - 21

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      59 Participants Needed

      TROP2 ADC + Anti-PD-1 for Solid Cancer

      Boston, Massachusetts
      This trial tests a new cancer treatment that targets and kills cancer cells directly and boosts the immune system. It is for patients with advanced cancers that don't respond to usual treatments. The study aims to find the best dose and safety of this new treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active CNS Metastases, Leptomeningeal Disease, Others
      Must Not Be Taking:Systemic Steroids

      300 Participants Needed

      BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

      Boston, Massachusetts
      BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Resistant Mutations, Interstitial Lung Disease, Others
      Must Be Taking:EGFR TKIs

      200 Participants Needed

      Tocilizumab + Atezolizumab + Radiation Therapy for Glioblastoma

      Worcester, Massachusetts
      This trial tests a combination of tocilizumab, atezolizumab, and precise radiation therapy in patients with recurrent glioblastoma. Tocilizumab reduces inflammation, atezolizumab boosts the immune system, and the radiation targets the tumor. The goal is to make the tumor more responsive to treatment and improve patient outcomes.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:IDH Mutation, Bevacizumab, Transplant, Others
      Must Not Be Taking:Anti-PD-1, Anti-PD-L1, Anti-CTLA-4, Others

      59 Participants Needed

      GammaTile + Stupp Protocol for Glioblastoma

      Providence, Rhode Island
      This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:IDH Mutated Glioma, Prior Chemotherapy, Others
      Must Be Taking:Temozolomide

      61 Participants Needed

      Eflornithine + Temozolomide for Glioblastoma

      Providence, Rhode Island
      The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Recurrent Cancer, Cardiac Disease, Others
      Must Be Taking:Temozolomide

      66 Participants Needed

      DSC-MRI for Recurrent Glioblastoma

      Providence, Rhode Island
      This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Intratumoral Hemorrhage, Others
      Must Be Taking:Bevacizumab

      146 Participants Needed

      OKN-007 + Temozolomide for Recurrent Brain Cancer

      Providence, Rhode Island
      This trial is testing a new drug called OKN-007 combined with a chemotherapy drug, temozolomide, in patients whose brain cancer has returned after standard treatments. OKN-007 may help reduce tumor growth and make the chemotherapy more effective. Temozolomide is effective in treating malignant brain tumors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Second Malignancy, Systemic Disorders, Others
      Must Be Taking:Temozolomide

      57 Participants Needed

      Abemaciclib Combination Therapy for Neuroblastoma

      Providence, Rhode Island
      The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:< 21

      Key Eligibility Criteria

      Disqualifiers:Transplant, Pregnancy, Infections, Others
      Must Not Be Taking:CYP3A Inhibitors, UGT1A1 Inhibitors

      47 Participants Needed

      Ipilimumab + Nivolumab + Radiation for Glioblastoma

      Sanford, Maine
      This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Autoimmune Disease, Others
      Must Not Be Taking:Corticosteroids, Warfarin

      159 Participants Needed

      Nivolumab + Radiation + Bevacizumab for Glioblastoma

      Hartford, Connecticut
      This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Hypertension, Autoimmune, Others
      Must Not Be Taking:Anti-CTLA-4, Anti-PD-1

      39 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40
      Match to a Glioblastoma Trial

      Lomustine + Standard Therapy for Glioblastoma

      Lebanon, New Hampshire
      This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Prior Malignancy, Others
      Must Not Be Taking:Antidepressants, Immunotherapy, Others

      306 Participants Needed

      CONVIVO System for Brain Tumor Detection

      Lebanon, New Hampshire
      The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventional histologic evaluation of targeted biopsies from imaged tissue. The study team hypothesize that there will be a high degree of correlation between images obtained with the CONVIVO system and conventional histologic interpretation.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Children, FNa Allergy

      30 Participants Needed

      Immunotherapy for Brain Tumor

      Lebanon, New Hampshire
      This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden). Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Diseases, Active Malignancy, Others
      Must Not Be Taking:Checkpoint Inhibitors, Bevacizumab

      37 Participants Needed

      NanO2 for Glioblastoma

      New Haven, Connecticut
      This trial is testing a new treatment that delivers more oxygen to tumors. It aims to help patients with a specific type of brain cancer by making radiation therapy more effective. By increasing oxygen levels in the tumor, the treatment helps radiation work better at killing cancer cells.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Recurrent Glioblastoma, Stroke, MI, Others
      Must Be Taking:Temozolomide

      87 Participants Needed

      Triapine + Radiation Therapy for Brain Cancer

      New Haven, Connecticut
      This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:G6PD Deficiency, Uncontrolled Illness, Others
      Must Not Be Taking:Methemoglobinemia-inducing Drugs

      30 Participants Needed

      Brigimadlin + Radiation for Glioblastoma

      New Haven, Connecticut
      This trial tests BI 907828, a new drug for treating brain tumors. It targets adults with newly diagnosed glioblastoma. The drug works by blocking a protein that helps cancer cells grow. The study aims to see how well the drug is absorbed in the tumor and find the highest safe dose when combined with radiation therapy.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:TP53 Mutant, IDH Mutant, Others
      Must Not Be Taking:Restricted Medications

      24 Participants Needed

      fb-PMT for Glioblastoma

      New Haven, Connecticut
      This trial is testing fb-PMT, a new drug that targets many signals cancer cells use to grow, on patients with recurrent Glioblastoma. The drug can enter the brain and disrupt cancer cell communication, potentially stopping their growth.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, Other Cancer, Pregnancy, Others
      Must Not Be Taking:Bevacizumab, QT Prolonging Drugs

      34 Participants Needed

      Tamoxifen vs Etoposide for Recurrent Glioblastoma

      Edmonton, Alberta
      The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Concurrent Malignancy, Hypertension, Thrombosis, Others

      60 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Glioblastoma clinical trials in Boston, MA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Glioblastoma clinical trials in Boston, MA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Glioblastoma trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA for Glioblastoma is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Glioblastoma medical study in Boston, MA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Glioblastoma clinical trials in Boston, MA?

      Most recently, we added Lorlatinib for Brain Tumors, CUE-102 for Glioblastoma and Triapine + Radiation Therapy for Brain Cancer to the Power online platform.